Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$38.77+6.8%$37.50$30.04▼$67.88$3.35B1.881.68 million shs2.93 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+1.99%+0.24%-6.78%-26.97%-36.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.0867 of 5 stars4.31.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7585.07% UpsideCurrent Analyst Ratings BreakdownLatest CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.005/7/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $81.005/7/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $82.004/9/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/18/2025CRSPCRISPR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$89.00 ➝ $82.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M95.67N/AN/A$22.52 per share1.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)Latest CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableCRSP HeadlinesRecent News About These CompaniesCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseMay 16 at 7:15 AM | marketbeat.comCresset Asset Management LLC Sells 12,037 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)May 16 at 4:34 AM | marketbeat.comCRISPR is used in landmark treatment to correct genetic misspelling of a single patientMay 15 at 3:03 PM | statnews.comAre Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?May 15 at 4:57 AM | msn.com2 Biotech Stocks That Are Screaming Buys in MayMay 14 at 6:08 AM | aol.comCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItMay 13 at 10:00 AM | zacks.comWhat is Chardan Capital's Forecast for CRSP FY2025 Earnings?May 13 at 3:25 AM | americanbankingnews.comChardan Capital Issues Optimistic Forecast for CRSP EarningsMay 13 at 3:14 AM | marketbeat.comQ2 EPS Estimate for CRISPR Therapeutics Raised by AnalystMay 13 at 2:09 AM | marketbeat.comCRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on WednesdayMay 13 at 1:52 AM | americanbankingnews.comCan Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?May 12, 2025 | fool.comHC Wainwright Issues Optimistic Estimate for CRSP EarningsMay 12, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $42.00 at BarclaysMay 11, 2025 | marketbeat.comQ2 EPS Forecast for CRISPR Therapeutics Lowered by AnalystMay 11, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CRSP EarningsMay 11, 2025 | marketbeat.comWilliam Blair Expects Lower Earnings for CRISPR TherapeuticsMay 11, 2025 | marketbeat.comCRSP FY2025 EPS Estimate Raised by Cantor FitzgeraldMay 11, 2025 | americanbankingnews.comQ2 EPS Forecast for CRISPR Therapeutics Decreased by AnalystMay 11, 2025 | americanbankingnews.comLeerink Partnrs Has Negative Outlook of CRSP Q2 EarningsMay 11, 2025 | americanbankingnews.com3 Monster Stocks to Hold for the Next 10 YearsMay 10, 2025 | fool.comBenjamin Edwards Inc. Acquires 12,359 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)May 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseBy Chris Markoch | May 16, 2025View CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseCRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$38.77 +2.46 (+6.77%) Closing price 04:00 PM EasternExtended Trading$38.20 -0.57 (-1.47%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
